FNCH

Finch Therapeutics Group Inc

(NO DISGNOSTIC SUBSTANCES)
LIFE SCIENCES

Prices are adjusted according to historical splits.

Finch Therapeutics Group Inc Stock Price

Vitals

Today's Low:
$1.2400
Today's High:
$1.3000
Open Price:
$1.2600
52W Low:
$1.24
52W High:
$17.39
Prev. Close:
$1.3000
Volume:
40646

Company Statistics

Market Cap.:
$0.059 billion
Book Value:
3.355
Revenue TTM:
$0.013 billion
Operating Margin TTM:
-585%
Gross Profit TTM:
$-0.039 billion
Gross Profit TTM:
$-0.039 billion
Profit Margin:
0%
Return on Assets TTM:
-19.7%
Return on Equity TTM:
-39.4%

Company Profile

Finch Therapeutics Group Inc had its IPO on 2021-03-19 under the ticker symbol FNCH.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Finch Therapeutics Group Inc has a staff strength of 0 employees.

Stock update

Shares of Finch Therapeutics Group Inc opened at $1.26 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $1.24 - $1.3, and closed at $1.24.

This is a -4.49% slip from the previous day's closing price.

A total volume of 40,646 shares were traded at the close of the day’s session.

In the last one week, shares of Finch Therapeutics Group Inc have slipped by -37.92%.

Finch Therapeutics Group Inc's Key Ratios

Finch Therapeutics Group Inc has a market cap of $0.059 billion, indicating a price to book ratio of 0.402 and a price to sales ratio of 4.603.

In the last 12-months Finch Therapeutics Group Inc’s revenue was $0.013 billion with a gross profit of $-0.039 billion and an EBITDA of $-0.071 billion. The EBITDA ratio measures Finch Therapeutics Group Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Finch Therapeutics Group Inc’s operating margin was -585% while its return on assets stood at -19.7% with a return of equity of -39.4%.

In Q2, Finch Therapeutics Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 87.2%.

Finch Therapeutics Group Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-1.445 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Finch Therapeutics Group Inc’s profitability.

Finch Therapeutics Group Inc stock is trading at a EV to sales ratio of 1.125 and a EV to EBITDA ratio of -0.203. Its price to sales ratio in the trailing 12-months stood at 4.603.

Finch Therapeutics Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Finch Therapeutics Group Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Finch Therapeutics Group Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Finch Therapeutics Group Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Finch Therapeutics Group Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Finch Therapeutics Group Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$1.24
52-Week High
$17.39
52-Week Low
$1.24
Analyst Target Price
$13.25

Finch Therapeutics Group Inc stock is currently trading at $1.24 per share. It touched a 52-week high of $17.39 and a 52-week low of $17.39. Analysts tracking the stock have a 12-month average target price of $13.25.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Finch Therapeutics Group Inc

The stock symbol (also called stock or share ticker) of Finch Therapeutics Group Inc is FNCH

The IPO of Finch Therapeutics Group Inc took place on 2021-03-19

Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))

Last Price
Chg
Chg%
$2.05
-0.01
-0.49%
$0.7
-0.06
-7.89%
$0.83
-0.06
-6.68%
$1.3
-0.07
-5.11%
Biomx Inc (PHGE)
$0.36
-0.01
-2.54%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutic company, is developing a new class of orally administered biologic drugs in the United States. The company is headquartered in Somerville, Massachusetts.

Address

200 INNER BELT ROAD, SOMERVILLE, MA, US